PURPOSE: Resveratrol (3,5,4'-trihydroxy-trans-stilbene) is a naturally occurring polyphenol with a broad range of possible health benefits, including anti-cancer activity. However, the biological activity of resveratrol may be limited by poor absorption and first-pass metabolism: only low plasma concentrations of resveratrol are seen following oral administration, and metabolism to glucuronide and sulfate conjugates is rapid. Methylated polyphenol analogs (such as pterostilbene [3,5-dimethoxy-4'-hydroxy-trans-stilbene], the dimethylether analog of resveratrol) may overcome these limitations to pharmacologic efficacy. The present study was designed to compare the bioavailability, pharmacokinetics, and metabolism of resveratrol and pterostilbene following equimolar oral dosing in rats. METHODS: The agents were administered orally via gavage for 14 consecutive days at 50 or 150 mg/kg/day for resveratrol and 56 or 168 mg/kg/day for pterostilbene. Two additional groups were dosed once intravenously with 10 and 11.2 mg/kg for resveratrol and pterostilbene, respectively. Plasma concentrations of agents and metabolites were measured using a high-pressure liquid chromatograph-tandem mass spectrometer system. Noncompartmental analysis was used to derive pharmacokinetic parameters. RESULTS: Resveratrol and pterostilbene were approximately 20 and 80% bioavailable, respectively. Following oral dosing, plasma levels of pterostilbene and pterostilbene sulfate were markedly greater than were plasma levels of resveratrol and resveratrol sulfate. Although plasma levels of resveratrol glucuronide exceeded those of pterostilbene glucuronide, those differences were smaller than those of the parent drugs and sulfate metabolites. CONCLUSIONS: When administered orally, pterostilbene demonstrates greater bioavailability and total plasma levels of both the parent compound and metabolites than does resveratrol. These differences in agent pharmacokinetics suggest that the in vivo biological activity of equimolar doses of pterostilbene may be greater than that of resveratrol.
PURPOSE:Resveratrol (3,5,4'-trihydroxy-trans-stilbene) is a naturally occurring polyphenol with a broad range of possible health benefits, including anti-cancer activity. However, the biological activity of resveratrol may be limited by poor absorption and first-pass metabolism: only low plasma concentrations of resveratrol are seen following oral administration, and metabolism to glucuronide and sulfate conjugates is rapid. Methylated polyphenol analogs (such as pterostilbene [3,5-dimethoxy-4'-hydroxy-trans-stilbene], the dimethylether analog of resveratrol) may overcome these limitations to pharmacologic efficacy. The present study was designed to compare the bioavailability, pharmacokinetics, and metabolism of resveratrol and pterostilbene following equimolar oral dosing in rats. METHODS: The agents were administered orally via gavage for 14 consecutive days at 50 or 150 mg/kg/day for resveratrol and 56 or 168 mg/kg/day for pterostilbene. Two additional groups were dosed once intravenously with 10 and 11.2 mg/kg for resveratrol and pterostilbene, respectively. Plasma concentrations of agents and metabolites were measured using a high-pressure liquid chromatograph-tandem mass spectrometer system. Noncompartmental analysis was used to derive pharmacokinetic parameters. RESULTS:Resveratrol and pterostilbene were approximately 20 and 80% bioavailable, respectively. Following oral dosing, plasma levels of pterostilbene and pterostilbene sulfate were markedly greater than were plasma levels of resveratrol and resveratrol sulfate. Although plasma levels of resveratrol glucuronide exceeded those of pterostilbene glucuronide, those differences were smaller than those of the parent drugs and sulfate metabolites. CONCLUSIONS: When administered orally, pterostilbene demonstrates greater bioavailability and total plasma levels of both the parent compound and metabolites than does resveratrol. These differences in agent pharmacokinetics suggest that the in vivo biological activity of equimolar doses of pterostilbene may be greater than that of resveratrol.
Authors: Nanjoo Suh; Shiby Paul; Xingpei Hao; Barbara Simi; Hang Xiao; Agnes M Rimando; Bandaru S Reddy Journal: Clin Cancer Res Date: 2007-01-01 Impact factor: 12.531
Authors: G Kuhnle; J P Spencer; G Chowrimootoo; H Schroeter; E S Debnam; S K Srai; C Rice-Evans; U Hahn Journal: Biochem Biophys Res Commun Date: 2000-05-27 Impact factor: 3.575
Authors: Patrick W Mannal; Juile A Alosi; John G Schneider; Debbie E McDonald; David W McFadden Journal: J Gastrointest Surg Date: 2010-02-06 Impact factor: 3.452
Authors: Victoria A Brown; Ketan R Patel; Maria Viskaduraki; James A Crowell; Marjorie Perloff; Tristan D Booth; Grygoriy Vasilinin; Ananda Sen; Anna Maria Schinas; Gianfranca Piccirilli; Karen Brown; William P Steward; Andreas J Gescher; Dean E Brenner Journal: Cancer Res Date: 2010-10-08 Impact factor: 12.701
Authors: Shiby Paul; Andrew J DeCastro; Hong Jin Lee; Amanda K Smolarek; Jae Young So; Barbara Simi; Chung Xiou Wang; Renping Zhou; Agnes M Rimando; Nanjoo Suh Journal: Carcinogenesis Date: 2010-01-08 Impact factor: 4.944
Authors: Miguel Muzzio; Zhihua Huang; Shu-Chieh Hu; William D Johnson; David L McCormick; Izet M Kapetanovic Journal: J Pharm Biomed Anal Date: 2011-10-25 Impact factor: 3.935
Authors: Alonso Heredia; Charles Davis; Mohammed N Amin; Nhut M Le; Mark A Wainberg; Maureen Oliveira; Steven G Deeks; Lai-Xi Wang; Robert R Redfield Journal: AIDS Date: 2014-01-28 Impact factor: 4.177